Cargando…
Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting
Chemotherapy-induced nausea and vomiting (CINV) are among the most feared and distressing symptoms experienced by patients with cancer. The knowledge of the pathogenesis and neuropharmacology of CINV has expanded enormously over the last decades, the most significant discoveries being the role of 5-...
Autores principales: | Ruhlmann, Christina, Herrstedt, Jørn |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697542/ https://www.ncbi.nlm.nih.gov/pubmed/19536319 |
Ejemplares similares
-
Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes
por: Herrstedt, Jørn, et al.
Publicado: (2021) -
Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron
por: Adams, Laurel M., et al.
Publicado: (2009) -
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone
por: Johnson, Brendan, et al.
Publicado: (2009) -
Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK(1)) receptor antagonists
por: Bošnjak, Snežana M., et al.
Publicado: (2017) -
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)